Definitive Contract HHSN261201200039C
Award Date 9/28/12
Potential Completion Date 3/2/16
Potential Value $1.5M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cambridge, MA 02138, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $199,892.00 federal contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a for-profit small business. The contract is for basic research and development in the "OTHER FUNCTIONS R & D- BIOMEDICAL (BASIC RESEARCH)" domain as part of the SBIR Program Phase I. The contract is a definitive, firm fixed-price agreement with a completion date of June 21, 2013. This contract award has a total small business set-aside designation.
- <p>This is a $249,748.00 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Evorx Technologies, Inc., a small disadvantaged business. The contract is for the development of "NOVEL MOLECULAR IMAGING AGENTS FOR HER2+ BREAST CANCER" and has a completion date of December 19, 2014. This contract award was set aside for total small business participation.</p>
- <p>This is a $1,784.00 firm fixed price delivery order contract awarded by the National Cancer Institute, a civilian agency, to Battelle Memorial Institute for initial administrative charges related to a pre-clinical toxicology study of a drug being developed for cancer patients. The contract is an order placed under the Toxicology of Drugs Developed for Cancer Patients indefinite-delivery indefinite-quantity (IDIQ) contract vehicle. No set-aside was used for this award.</p>
- This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Buffalo Biolabs, LLC, a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) program. The award amount is $1,496,764.00 and the period of performance is until October 31, 2014. The contract is a Phase II SBIR action, which indicates it is for the continued development and testing of a promising technology that was previously funded under a...
- <p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>
- This is a federal contract award from the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a small business contractor. The contract has a Ceiling Value of $199,860.00 and is a Definitive Contract with a Firm Fixed Price pricing type. The contract was awarded on September 30, 2010 with an Ultimate Completion Date of June 29, 2011. The place of performance is Boston, MA. This appears to be a standalone contract award and not part of a larger contract vehicle. The...
- <p>This is a $299,990.00 firm-fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Evorx Technologies, Inc., a small disadvantaged business. The contract was set aside for small businesses. The award is for an unspecified product or service related to the NCI's mission, with a period of performance ending on February 28, 2017. No additional details about the specific requirements or work to be performed are provided.</p>
- This is a federal contract award to Biotex, Inc., a for-profit organization and manufacturer of goods, by the National Cancer Institute (NCI), a civilian agency. The contract is for the "Development of Alternative Affinity Capture Reagents for Cancer Proteomics Research" under the Small Business Innovation Research (SBIR) Phase II program, with a total ceiling value of $749,995.92. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate...
- <p>This is a $994,198.78 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Precision For Medicine (TX), Inc. on September 20, 2013. The contract is for research and development in biomedical (basic research) and has a period of performance through September 19, 2015. The contract is designated as a total small business set-aside.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Matrisome Bio, Inc. for the development of "Novel Theranostic Radioligands Targeting Disease-Specific Extracellular Matrix Components Specific to Tumor and Metastatic Lesions in Patients Suffering from Hereditary Breast and Ovarian Cancer (HBOC)." The contract has a firm fixed price of $354,456.00 and a completion date of September 14, 2026. As this...